A Phase 1b Study to Investigate Safety and Tolerability of ARGX-119 in Adult Participants With DOK7-Congenital Myasthenic Syndromes (CMS)

PHASE1Active, not recruitingINTERVENTIONAL
Enrollment

16

Participants

Timeline

Start Date

September 24, 2024

Primary Completion Date

November 25, 2025

Study Completion Date

November 25, 2025

Conditions
Congenital Myasthenic Syndrome
Interventions
BIOLOGICAL

ARGX-119

Intravenous infusion of ARGX-119

OTHER

Placebo

Intravenous infusion of placebo

Trial Locations (9)

13385

CHU - Hospital de la Timone, Marseille

20133

Fondazione IRCCS Istituto Neurologico Carlo Besta, Milan

46026

Universitat de Valencia - Hospital Universitari i Politecnic La Fe de Valencia (Hospital La Fe Bulevar Sur), Valencia

60611

Ann and Robert H Lurie Childrens Hospital of Chicago, Chicago

75013

Group Hospitalier Pitie-Salpetriere, Paris

95817

UC Davis Medical Center, Sacramento

K1Y 4E9

Ottawa Hospital Research Institute - Civic Campus, Ottawa

BT16 1RH

Clinical Trials Centre - South Eastern Health and Social Care Trust - The Ulster Hospital, Belfast

OX3 9DU

John Radcliffe Hospital - Oxford University Hospitals NHS Foundation Trust, Oxford

Sponsors

Lead Sponsor

All Listed Sponsors
lead

argenx

INDUSTRY